These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 9702762)

  • 1. Biotech and pharma face more costly clinical trials.
    Brower V
    Nat Biotechnol; 1998 Aug; 16(8):714. PubMed ID: 9702762
    [No Abstract]   [Full Text] [Related]  

  • 2. Protecting human research subjects: ten common problems.
    Puglisi T
    Health Law News; 2000 Jun; 13(3):8, 15. PubMed ID: 12542046
    [No Abstract]   [Full Text] [Related]  

  • 3. Continued concern: human subject protection, the institutional review board, and continuing review.
    Hoffman S
    Tenn Law Rev; 2001; 68(4):725-70. PubMed ID: 16189912
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical trials face heightened scrutiny as science and commerce appear to merge.
    Lorman AJ
    J Biolaw Bus; 2001; 4(4):23-32. PubMed ID: 12751494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time for new rules on human subjects research?
    Dresser R
    Hastings Cent Rep; 1998; 28(6):23-4. PubMed ID: 9868606
    [No Abstract]   [Full Text] [Related]  

  • 6. Half-full or half-empty? Evaluating IRB performance.
    Mishkin B; Ariand N
    Prof Ethics Rep; 1998; 11(3):4-7. PubMed ID: 11657925
    [No Abstract]   [Full Text] [Related]  

  • 7. The IRB as deputy sheriff: proposed FDA regulation of the institutional review board.
    Huff TA
    Clin Res; 1979 Apr; 27(2):103-8. PubMed ID: 10241072
    [No Abstract]   [Full Text] [Related]  

  • 8. Toward a more comprehensive approach to protecting human subjects: the interface of data safety monitoring boards and institutional review boards in randomized clinical trials.
    Gordon VM; Sugarman J; Kass N
    IRB; 1998; 20(1):1-5. PubMed ID: 11655324
    [No Abstract]   [Full Text] [Related]  

  • 9. Institutional review boards in the university setting: review of pharmaceutical testing protocols, informed consent and ethical concerns.
    Kobasic DM
    J Coll Univ Law; 1988; 15(2):185-216. PubMed ID: 11659168
    [No Abstract]   [Full Text] [Related]  

  • 10. Commission says institutional review boards should change procedures now.
    Maloney DM
    Hum Res Rep; 1999 Jan; 14(1):1-2. PubMed ID: 11657555
    [No Abstract]   [Full Text] [Related]  

  • 11. IRB review of adverse events in investigational drug studies.
    Prentice ED; Gordon B
    IRB; 1997; 19(6):1-4. PubMed ID: 11656910
    [No Abstract]   [Full Text] [Related]  

  • 12. IRBs and pharmaceutical company funding of research.
    Jellinek MS; Levine RJ
    IRB; 1982 Oct; 4(8):9-10. PubMed ID: 11651693
    [No Abstract]   [Full Text] [Related]  

  • 13. Institutional review boards (IRBs) failed to use steps to protect vulnerable research subjects.
    Maloney DM
    Hum Res Rep; 2003 Jun; 18(6):6-7. PubMed ID: 15119342
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA revises informed consent regulations for emergency research.
    Menasché A; Levine RJ
    IRB; 1995; 17(5-6):19-22. PubMed ID: 11653359
    [No Abstract]   [Full Text] [Related]  

  • 15. Sweeping bioethical reform proposals contemplated for trials.
    Fox JL
    Nat Biotechnol; 2000 Dec; 18(12):1237. PubMed ID: 11101792
    [No Abstract]   [Full Text] [Related]  

  • 16. IRBs and epidemiologic research: how inappropriate restrictions hamper studies.
    Cann CI; Rothman KJ
    IRB; 1984; 6(4):5-7. PubMed ID: 11649562
    [No Abstract]   [Full Text] [Related]  

  • 17. Why HHS should reconsider its proposed exemption for social policy experiments.
    Abram MB;
    IRB; 1982 May; 4(5):10-2. PubMed ID: 11649408
    [No Abstract]   [Full Text] [Related]  

  • 18. Multicenter trials and subject eligibility: should local IRBs play a role?
    Freedman B
    IRB; 1994; 16(1-2):1-6. PubMed ID: 11652320
    [No Abstract]   [Full Text] [Related]  

  • 19. Federal investigation concludes that institutional review boards are in trouble.
    Maloney DM
    Hum Res Rep; 1998 Aug; 13(8):1-2. PubMed ID: 11657190
    [No Abstract]   [Full Text] [Related]  

  • 20. Federal report says protection of human subjects is threatened by numerous factors.
    Maloney DM
    Hum Res Rep; 1996 May; 11(5):1-3. PubMed ID: 11654438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.